Kowa Announces the Efficacy and Safety of a Novel Rho Kinase Inhibitor (K-115) in the Treatment of Glaucoma in ARVO 2011
TOKYO--(BUSINESS WIRE)--May 10, 2011 - Kowa Company Ltd, (Headquarters: Nagoya, Japan, President & CEO: Yoshihiro Miwa, "Kowa") today announced the results of two clinical studies and a non-clinical study of a drug candidate for glaucoma and ocular hypertension (K-115). The results were presented as three posters at The Association for Research in Vision and Ophthalmology (ARVO) 2011 meeting in Fort Lauderdale, Florida, USA. The results of the two clinical studies can be read as an E-poster on the ARVO 2011 website during and after the conference.
K-115, a Rho kinase inhibitor, lowers intraocular pressure (IOP) by increasing conventional aqueous outflow. Consequently, additive effects are anticipated when K-115 is used in combination with other anti-glaucoma drugs. K-115 will also be developed as monotherapy for glaucoma.
Based on the results of these Phase 2 studies, Kowa will continue its clinical development program in Japan and will initiate Phase 3 studies with the aim of achieving marketing authorization as the world's first Rho kinase inhibitor for the treatment of glaucoma and ocular hypertension.
Presentations accepted by ARVO 2011 are as follows:
- Phase 2 clinical pharmacology study: Efficacy and Safety of the Rho Kinase Inhibitor, K-115, over 24 Hours in Patients with Primary Open-angle Glaucoma and Ocular Hypertension (E-Poster Presentation)*
- Phase 2 dose-response study: Ocular Hypotensive Dose-response Efficacy and Safety of the Rho Kinase Inhibitor, K-115, in Patients with Primary Open-angle Glaucoma and Ocular Hypertension (E-Poster Presentation)*
- Non-clinical study: Ocular Hypotensive Mechanism Of K-115, A Rho-kinase Inhibitor, And Rho-kinase Expression In The Eye
*E-Poster can be browsed for 24 hours via ARVO2011 Online E-Poster Viewer System from May 01 to June 30, 2011
Kowa has made intraocular and lifestyle disease R&D priorities, and is endeavoring to develop and explore innovative medicines. In addition, Kowa focuses on three major activities: drug discovery, innovative formulation discovery, and the development of neo generics, and actively engages in R&D activities to satisfy unmet medical needs.
Contact: Kowa Company, Ltd.
Kazuhiro Kachi, +81-3-3279-7392 (Japanese inquiries only)
Kowa Research Institute, Inc.
Gary Gordon, +1-919-433-1607 (English Only)
Senior Vice president
Posted: May 2011